GSK announces CHMP of the EMA recommended expanding approval of Jemperli

GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy for first-line treatment of all adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This would include patients with mismatch repair proficient /microsatellite stable tumours, who represent 70-75% of patients diagnosed with endometrial cancer and who have limited treatment options. The CHMP opinion is one of the final steps prior to a marketing authorisation decision by the European Commission, with an approval decision expected in the first quarter of 2025.